Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $25 to $24.
Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $25 to $24.